ArticleJournal of orthopaedic surgery and research2020
Outcome of lung metastases due to bone giant cell tumor initially managed with observation.
Article in Journal of orthopaedic surgery and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era.Current oncology (Toronto, Ont.) · 2024Pooled it
- De novo osteosarcoma following prolonged denosumab treatment for giant cell tumor of bone at an anatomically distant site: a case report.Skeletal radiology · 2026Article
- Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities.Healthcare (Basel, Switzerland) · 2026Review
- Conversion to Complete, Parenchyma-Sparing Resection after Prolonged Denosumab for Bilateral Multifocal Pulmonary Metastases from Giant Cell Tumor of Bone: A Case Report.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Pulmonary metastasis of giant cell tumor of bone 29 years after local recurrence resection: implications for Long-Term surveillance.Discover oncology · 2025Article
- Giant cell tumor of the bone with fatal pulmonary metastasis: A case report.SAGE open medical case reports · 2025Article
- Giant cell tumor of bone and secondary osteoarthritis.Heliyon · 2024Review
- Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update.Current oncology (Toronto, Ont.) · 2024Review
- Non‑surgical outcomes and risk factors for pulmonary metastasis from giant cell tumor of bone.Oncology letters · 2023Article
- Management of giant cell tumors of the distal radius.Journal of orthopaedics · 2023Article
- Case Report: Unresectable pulmonary metastases of a giant cell tumor of bone treated with denosumab: a case report and review of literature.Frontiers in oncology · 2023Article
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.International journal of molecular sciences · 2022Review
- Metastatic giant cell tumour of bone: a narrative review of management options and approaches.ANZ journal of surgery · 2022Review
- Recurrent Giant Cell Tumor of Distal Radius with Pulmonary Metastasis: A Case Report.Journal of orthopaedic case reports · 2021Article
- Risk factors and oncological outcomes of pulmonary metastasis in patients with giant cell tumor of bone.Journal of clinical orthopaedics and trauma · 2021Article
- What's new in musculoskeletal oncology.BMC musculoskeletal disorders · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe outcomes of patients with lung metastases from giant cell tumor of bone (GCTB) vary from spontaneous regression to uncontrolled growth. To investigate whether observation is an appropriate first-line management approach for patients with lung metastases from GCTB, we evaluated the outcomes of patients who were initially managed by observation.
methodsWe retrospectively reviewed the data of 22 patients with lung metastases from histologically confirmed GCTB who received observation as a first-line treatment approach. The median follow-up period was 116 months.
resultsDisease progression occurred in 12 patients (54.5%). The median interval between the discovery of lung metastases and progression was 8 months. Eight patients underwent metastasectomy following initial observation. The median interval between the discovery of lung metastases and treatment by metastasectomy was 13.5 months. None of the patients experienced spontaneous regression. Of the 22 patients, 36.4% needed a metastasectomy, and 9.1% required denosumab treatment during the course of the follow-up period. Disease progression occurred in 45.5% of the 11 patients with lung nodules ≤ 5 mm, while all five of the patients with lung nodules > 5 mm experienced disease progression. Progression-free survival was significantly worse in the group with lung nodules > 5 mm compared to the group with lung nodules ≤ 5 mm (p = 0.022).
conclusionsObservation is a safe first-line method of managing patients with lung metastases from GCTB. According to radiological imaging, approximately half of the patients progressed, and approximately half required a metastasectomy or denosumab treatment. However, patients with lung nodules > 5 mm should receive careful observation because of the high rate of disease progression in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.